表紙
市場調査レポート

Baricitinib (関節リウマチ治療薬) - 2023年までの予測と市場分析

Baricitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 258665
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Baricitinib (関節リウマチ治療薬) - 2023年までの予測と市場分析 Baricitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 88 Pages
概要

関節リウマチ (RA) は、慢性の自己免疫疾患で、関節の炎症や変形を引き起こします。世界の主要10ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、オーストラリア、中国、インド) の患者数は700万人を超え、2023年までに850万人に達すると見られています。これまで、RAの兆候や症状にはTNF阻害薬が有効でしたが、バイオシミラー、新規生物製剤、経口のJAK阻害薬などの導入によって、情勢は急速に変化しています。

当レポートでは、RAの治療薬であるBaricitinibについて調査分析し、疾患の概要と治療ガイドライン、競合情勢、製品情報、売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 症状
  • 予後
  • QOL

第4章 疾患の管理

  • 診断と治療の概要
    • 診断
    • 治療のガイドライン
    • 主要な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 アンメットニーズと機会

  • 概要
  • 費用対効果の高い治療の開発
  • バイオマーカーで治療への反応性を予測
  • RAの早期診断
  • 個別化治療法

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 Baricitinib

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC511DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Eli Lilly and Incyte are jointly developing baricitinib, an oral JAK inhibitor, for the treatment of patients with moderate to severe RA. Baricitinib has roughly equal affinity for JAK1 and JAK2, preventing the intracellular signaling cascades that lead to the production of IL-6 and IL-23, thereby reducing inflammation.

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Baricitinib including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Baricitinib for the top 10 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Baricitinib performance.
  • Obtain sales forecast for Baricitinib from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Development of Cost-Effective Therapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Biomarkers to Predict Responsiveness to Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Early Diagnosis of RA
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Baricitinib

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed RA Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic and Biosimilar Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Reviewer
    • 9.7.3. Therapy Area Director
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Unmet Need and Opportunity in RA, 2014
  • Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 11: Product Profile - Baricitinib
  • Table 12: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12
  • Table 13: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52
  • Table 14: Baricitinib Phase IIb Trial, Part A: Safety at Week 12
  • Table 15: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12
  • Table 16: Baricitinib SWOT Analysis, 2014
  • Table 17: Global Sales Forecasts ($m) for Baricitinib, 2013-2023
  • Table 18: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: RA - Phase II-III Pipeline, 2014
  • Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 8: Clinical and Commercial Positioning of Baricitinib
Back to Top